Secnidazole

Secnidazole
Clinical data
Trade names	Solosec
Other names	PM-185184; RP-14539; SYM-1219
AHFS/Drugs.com	International Drug Names
License data	US DailyMed: Secnidazole;
Routes of; administration	Oral
ATC code	P01AB07 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 1-(2-Methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol;
CAS Number	3366-95-8 ;
PubChem CID	71815;
ChemSpider	64839 ;
UNII	R3459K699K;
KEGG	D07353 ;
ChEBI	CHEBI:140628;
ChEMBL	ChEMBL498847 ;
CompTox Dashboard (EPA)	DTXSID3045934 ;
ECHA InfoCard	100.020.123
Chemical and physical data
Formula	C7H11N3O3
Molar mass	185.183 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-] [N+](=O)c1cnc(n1CC(O)C)C;
	InChI InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3 ; Key:KPQZUUQMTUIKBP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Secnidazole (trade names Flagentyl, Sindose, Secnil, Solosec) is a nitroimidazole anti-infective used to treat bacterial vaginosis and trichomoniasis. It is taken orally.

Structurally it actually methyl-metronidazole. Effectiveness in the treatment of dientamoebiasis has been reported. It has also been tested against Atopobium vaginae.

In the United States, secnidazole is FDA-approved for the treatment of bacterial vaginosis and trichomoniasis in adult women. It was approved in the United States in 2017.